Exploring the use of GLP1 analogues as appetite suppressants, the chapter critiques the pharmaceutical industry's push to classify obesity as a genetic disease for increased insurance coverage. Emphasizing lifestyle changes over medication, it discusses historical weight loss drugs and the importance of addressing root cause physiology. The conversation also touches on cold exposure, metabolic health benefits, fasting, and meal timing impacts on glucose and insulin responses.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode